The internet answers “peptide injection sites” in ten seconds with a drawing of a stomach, a thigh and an arm. The labels take longer, and they do not agree with each other.
Five peptide drugs carry FDA approval and a filed label. Read their administration sections side by side and you get four different maps, one hard prohibition and a rotation rule that carries more weight than any of the drawings. The short answer: the approved sites are the abdomen, the thigh and the upper arm, two of those five drugs are restricted to fewer zones, and the site has to change with each dose.
That gap matters because most people searching this phrase are not holding an approved pen. They are holding a vial.
Peptide Injection Sites: The Approved Map – Four Answers From Five Labels
Start with the two brands people know best, because one manufacturer sells both of them and still splits its own advice.
Ozempic (semaglutide) section 2.1 tells the patient to inject subcutaneously in the abdomen, thigh or upper arm, then adds a sentence that reads like a warning: change (rotate) your injection site with each injection, and do not use the same site for each injection. The same label allows an Ozempic dose and an insulin dose in one body area, on the condition that the two injections do not sit right next to each other.
Wegovy, the weight-loss brand built on the same molecule, lists the same three zones and then draws a line the Ozempic label leaves out: do not inject Wegovy into a muscle (intramuscularly) or vein (intravenously). It also notes that the time of day and the injection site can change without any dose adjustment.
Zepbound (tirzepatide) lists the abdomen, the thigh and the upper arm, with the back of that arm reserved for a dose another person gives. Its patient instructions carry the most useful sentence in the set: you may use the same area of your body, but choose a different injection site in that area. That line is the difference between rotating and going through the motions of rotating.
Then the map narrows. Egrifta WR (tesamorelin) section 2.1 permits the abdomen and nothing else. Rotate injection sites to different areas of the abdomen. Do not inject into scar tissue, bruises or the navel. A peptide drug with years on the market, and its label will not let a patient use a thigh.
Vyleesi (bremelanotide) permits the abdomen or the thigh through an autoinjector, with no upper arm option at all.
Four maps from five labels. A diagram on a supplement blog cannot know which one applies to the vial in front of you, and the vial carries no diagram.
The Rotation Rule – What the Evidence Underneath It Looks Like
Site rotation is the instruction that looks like housekeeping. The literature puts a number on it.
A systematic meta-analysis in the Journal of Diabetes Science and Technology, published July 2026, pooled 51 studies of risk factors for lipohypertrophy, the lumpy fat pads that form under skin that takes repeated injections. Incorrect injection site rotation carried a pooled odds ratio of 8.85, with a 95 percent confidence interval of 5.10 to 15.33. Needle reuse came second at 3.20. Sex, age and device type did not reach significance.
An international panel of 13 experts published consensus recommendations in Diabetes Research and Clinical Practice in September 2026 and put lipohypertrophy prevalence at 29 to 76 percent of insulin-treated people with diabetes. The panel named inadequate injection site rotation the strongest modifiable risk factor, and recommended a site examination at six months for the first two years of insulin therapy, then annually.
Two honest limits. That evidence comes from insulin, and no panel has run the same exercise on the peptides sold online. Lipohypertrophy also changes how a dose absorbs, which an insulin user reads in a glucose meter and a peptide user has no comparable way to measure.
The mechanism travels anyway. Skin that takes a needle in one spot, week after week, thickens.
What a Site Reaction Costs – One in Four on Egrifta
Tesamorelin’s label states the rate outright. Section 5.6 reports injection site reactions including erythema, pruritus, pain, irritation and bruising in 25 percent of Egrifta-treated patients against 14 percent on placebo during the first 26 weeks of trials, and tells prescribers to rotate sites across the abdomen to reduce them.
Compare the GLP-1 pens. Ozempic’s label reports injection site reactions in 0.2 percent of treated patients in placebo-controlled trials.
One in four against one in five hundred. The needle did not change and the technique did not change. The drug, the volume and the daily schedule changed. Anyone moving from a weekly pen to a daily vial is moving toward the first number, and the label that would warn them belongs to a product they are not using.
FDA’s own file on compounded GLP-1 drugs holds the case for the other failure. The agency describes one adverse event report tied to a product labelled as compounded tirzepatide from a pharmacy that, on FDA’s information, did not compound it. The symptoms were redness, site swelling, pain and a red lump at the injection site. A patient did the injection correctly, into a permitted zone, with a product that was not what the label said.
The site was fine. The vial was fiction.
Peptide Injection Sites Off the Label – What FDA’s Files Show
None of the peptides sold for self-injection on the research market carries an approved label, and the federal record says so in the plainest language available.
FDA’s page on bulk substances that may present significant safety risks, current as of 22 April 2026, addresses BPC-157 this way: the agency identified no, or only limited, safety-related information for the proposed routes of administration, and lacks sufficient information to know whether the drug would cause harm when administered to humans.
That same page carries a sharper warning about route, and it belongs in any conversation about where to put a needle. FDA notes a published study that identified serious adverse events including death when researchers gave ipamorelin intravenously for improving gastric motility, and states that it has not identified safety-related information for ipamorelin acetate by certain other injectable routes.
Read that twice. The route is the variable. Subcutaneous and intravenous are not two ways to take one drug, and the difference has been fatal.
FDA’s compounded GLP-1 page, current as of 1 October 2026, adds handling rules that vendor blogs skip. Multi-dose vials of sterile medication should be discarded within 28 days of first use, even when medication remains inside and even when the compounder’s instructions claim a longer window, because contamination risk climbs after that point. A new sterile needle and syringe for each dose, since reuse contaminates the medication.
The agency also reports multiple adverse events, some requiring hospitalization, from dosing errors with compounded injectable semaglutide, where patients measured a wrong dose or clinicians miscalculated one. Those errors happen at the point of injection, which makes the site, the syringe and the arithmetic one subject.
Anyone working through vial handling for the first time should start with what the federal record says about reconstitution before touching a stopper.
How to Choose a Site – The Rules the Labels Share
Strip out the brand differences and five labels leave a short common list.
Rotate with each dose. Pick a different spot inside the same zone rather than swapping zones entirely, which is the Zepbound wording and the practice the lipohypertrophy data supports.
Keep the needle out of scar tissue, bruises, stretch marks and the navel. Egrifta’s label names the first items and the navel outright, and the reasoning holds for any subcutaneous injection.
Stay out of muscle and vein. Wegovy’s label states the prohibition, and the ipamorelin record shows what a wrong route can cost.
Leave space between injections in one area. Ozempic’s label allows an insulin dose and a semaglutide dose in a single body area with distance between them.
Use a fresh needle. The meta-analysis puts needle reuse at a pooled odds ratio of 3.20 for lipohypertrophy, second only to skipped rotation.
Patients who would rather have a clinician pick and check the site can start from the clinic directory, where listings name the services each location provides.
Frequently asked questions
Where are peptide injection sites?
For the approved injectable peptides the permitted sites are the abdomen, the thigh and the upper arm. Egrifta WR restricts use to the abdomen, Vyleesi allows the abdomen or thigh, and Wegovy’s label forbids injecting into a muscle or a vein.
Can you inject peptides into your thigh?
Yes for Ozempic, Wegovy, Zepbound and Vyleesi, all of which list the thigh in their administration sections. No for Egrifta WR, whose label confines injection to the abdomen.
How often should you rotate a peptide injection site?
With each dose, according to the Ozempic, Wegovy, Zepbound and Egrifta labels. The September 2026 lipohypertrophy consensus names inadequate rotation the strongest modifiable risk factor, and a July 2026 meta-analysis of 51 studies put its pooled odds ratio at 8.85.
Is injecting a peptide into a vein or muscle dangerous?
Wegovy’s label prohibits both routes. FDA’s bulk substance file records a published study reporting serious adverse events including death when researchers administered ipamorelin intravenously, and states the agency has no safety-related information for certain other injectable routes.
Can you inject a peptide into a bruise or a scar?
Egrifta WR’s label directs patients away from scar tissue, bruises and the navel. Scar tissue is not the fat layer a subcutaneous dose targets, and it does not absorb predictably.
How long can you keep using a multi-dose peptide vial?
FDA recommends discarding a multi-dose vial of sterile medication within 28 days of first use, even when medication remains and even when the compounder says otherwise, with a new sterile needle and syringe for each dose.
Do peptide injection sites change how fast the drug works?
Wegovy’s label says the site can change without a dose adjustment. Absorption differences appear in insulin data as unpredictable readings, and no equivalent measurement exists for the unapproved peptides.
Sources: DailyMed SPL, OZEMPIC (semaglutide) injection, Novo Nordisk, sections 2.1 and 6.1, retrieved 17 October 2026 (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79). DailyMed SPL, WEGOVY (semaglutide) injection, Novo Nordisk, sections 2.1 and Medication Guide, retrieved 17 October 2026 (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b). DailyMed SPL, ZEPBOUND (tirzepatide) injection, Eli Lilly, section 2.1, retrieved 17 October 2026 (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b). DailyMed SPL, EGRIFTA WR (tesamorelin) for injection, Theratechnologies, published 3 August 2026, sections 2.1, 5.6 and 17 (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75). DailyMed SPL, VYLEESI (bremelanotide) injection, published 18 November 2025, section 2.1 (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf). FDA, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, content current as of 22 April 2026, retrieved 17 October 2026 (https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks). FDA, FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, content current as of 1 October 2026, retrieved 17 October 2026 (https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss). Risk factors for Lipohypertrophy in People With Insulin-Treated Diabetes: A Systematic Meta-Analysis, Journal of Diabetes Science and Technology, July 2026, PMID 40109173. Consensus Recommendations on Lipohypertrophy: Insights From an International Panel of Experts, Diabetes Research and Clinical Practice, September 2026, PMID 42398590.